Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
- 1 January 2018
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (1) , e33-e42
Abstract
No abstract availableKeywords
Funding Information
- Roche
- GlaxoSmithKline
- AbbVie
- Merck
- Novartis
This publication has 29 references indexed in Scilit:
- Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupThe Lancet Oncology, 2018
- Response assessment criteria for brain metastases: proposal from the RANO groupThe Lancet Oncology, 2015
- Local control after fractionated stereotactic radiation therapy for brain metastasesJournal of Neuro-Oncology, 2014
- Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupThe Lancet Oncology, 2013
- Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO groupThe Lancet Oncology, 2013
- Epidemiology of Brain MetastasesCurrent Oncology Reports, 2011
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyJournal of Clinical Oncology, 2011
- Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain MetastasesJAMA, 2006
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJAMA, 1998